DealsJun 3, 2026, 05:16 PM
Liminatus Pharma Raises $1.9M Via Warrant Exercise
AI Summary
Liminatus Pharma, Inc. announced a warrant exercise inducement offer, generating approximately $1.9 million in gross proceeds. The company entered into an agreement with a holder to exercise existing warrants at a reduced price of $0.18 per share, in exchange for issuing new warrants to purchase up to 20,688,000 shares of common stock. The net proceeds will be used for working capital and general corporate purposes. Maxim Group LLC served as the financial advisor for the transaction.
Key Highlights
- Liminatus Pharma entered a warrant exercise inducement offer with a holder to exercise 10,344,000 existing warrants at $0.18 per share.
- The company will issue new warrants to purchase up to 20,688,000 shares of common stock as inducement.
- Gross proceeds from the exercise of existing warrants are approximately $1,861,920, before fees.
- Proceeds will be used for working capital and general corporate purposes.
- New warrants are exercisable after stockholder approval and will expire five years from the approval date.
- Maxim Group LLC acted as financial advisor and will receive up to 8% of gross proceeds.
Price Impact
More from LIMN